Pfizer launches Robitussin flu tracker app

By Chris Gullo

robitussinThis week Pfizer launched Robitussin Relief Finder 2.0, a free iOS app that allows users to track flu activity nationwide and also find nearby stores that sell various types of Robitussin products.

The app enables users to find Robitussin products tailored to their flu symptoms via an in-app questionnaire, locate stores nearby selling Robitussin products, and receive coupons. A flu alerts tracker shows the level of flu activity in the user's area in an interface similar to Google's Flu Trends. The first version of the app, released earlier this year, offered limited features: the product finder and store locater based on zip code only.

The Robitussin 2.0 app is the latest in a handful of apps that Pfizer has released to the AppStore, including: Plan Q, a smoking cessation app intended for use with a cessation program (perhaps Pfizer's GETQUIT program that works in conjunction with Pfizer's Chantix pill?), as well as Pfizer Engage, an extension of their healthcare professional resource portal.

The pharma company's Pfizer Oncology RCC app appeared in a MobiHealthNews round-up of 10 iPhone apps created by pharma companies earlier this year, but, perhaps surprisingly, no longer appears in the AppStore.

In June Pfizer announced the first FDA-approved clinical drug trial involving all-electronic home-based reporting: The drug being “tested”, Detrol, is intended for use by patients with overactive bladders. However, the real purpose of the study, according to Pfizer, is to compare the mobile reporting of trial data to traditional methods of drug testing. Exco InTouch is providing some of the mobile technology involved in the trial.

Want to read stories as soon as they are posted? Follow MobiHealthNews on Facebook.
On Twitter? Be sure to follow MobiHealthNews for up-to-the-minute news and industry analysis.

Read on to see a slideshow of the app's features.


Upon launching the Find Relief section of the app, users can select whether the medication is intended for adults or children under the age of twelve.